Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant Humanized (from mouse) antibody to Human MS4A1. Obinutuzumab was approved under the tradename obinutuzumab by the US FDA in 2013, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients
IgG1 - kappa
Suitable for use in ELISA, FC, IP, FuncS, IF, Neut, WB and most other immunological methods.
MS4A1(membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens]
mmunoglobulin G1, anti-[Homo sapiens CD20 (membrane-spanning 4-domains subfamily A member 1, MS4A1, B lymphocyte surface antigenB1, Leu-16, Bp35)], humanized monoclonal antibody, GA101;gamma1 heavy chain (1-448) [humanized VH (Homo sapiens FR/Mus musculus CDR, Homo sapiens IGHJ4*01) [8.8.12] (1-119) – Homo sapiensIGHG1*01 (120-448)], (222-219') – disulfide withkappa light chain (1'-219') [humanized V-KAPPA (Homo sapiens FR/Mus musculus CDR, Homo sapiens IGKJ4*01) [11.3.9] (1'-112') – Homosapiens IGKC*01 (113'-219')]; (228-228'':231-231'') – bisdisulfide dimerHumanized monoclonal antibody specific for CD20. Humanized anti-CD20 mAb is being developed under a collaboration agreement withGenentech, a wholly-owned member of the Roche Group.
Purity >95% by SDS-PAGE.
B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. In humans CD20 is encoded by the MS4A1 gene.